Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics (NQ: FOLD )

11.00 +0.09 (+0.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,460,226
Open 11.13
Bid (Size) 10.95 (10)
Ask (Size) 11.00 (4)
Prev. Close 10.91
Today's Range 10.97 - 11.17
52wk Range 9.020 - 14.57
Shares Outstanding 266,555,274
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-22.75%
-22.75%
1 Month
-7.49%
-7.49%
3 Month
+12.24%
+12.24%
6 Month
-8.33%
-8.33%
1 Year
-14.73%
-14.73%

More News

Read More
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
From Amicus Therapeutics, Inc.
Via GlobeNewswire
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
Via Benzinga
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Stock Sees RS Rating Improve To 74
Via Investor's Business Daily
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
Via Investor's Business Daily
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Time to buy these 3 healthcare companies that raised revenue guidance?
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.